Abstract #0526

Magnetization Transfer-weighted Cardiac MRI in End Stage Renal Disease Quantifies Fibrosis and Identifies Biochemical Markers of Fibrosis without Gadolinium

Tori Stromp^1,2, Rebecca M Kidney², Tyler J Spear², Kristin N Andres³, Joshua C Kaine³, Steve W Leung⁴, and Moriel H Vandsburger^1,2,5,6

¹Physiology, University of Kentucky, Lexington, KY, United States, ²Cardiovascular Research Center, University of Kentucky, Lexington, KY, United States, ³College of Medicine, University of Kentucky, KY, United States, ⁴Gill Heart Institute, University of Kentucky, KY, United States, ⁵Biomedical Engineering, University of Kentucky, KY, United States, ⁶Bioengineering, University of California Berkeley, Berkeley, CA

Cardiac fibrosis is prevalent in end stage renal disease (ESRD). Contraindication to late gadolinium enhancement (LGE) cardiac MRI (CMR) obstructs diagnosis, treatment selection, and potential therapeutic target identification. Currently, ventricular hypertrophy and function are used as surrogate measures of fibrosis and correlates of biomarkers. We used magnetization transfer (MT) weighted CMR to quantify fibrosis, comparing to structure, function, and blood biomarkers. We recapitulated prevalent fibrosis found previously by LGE. Results suggest hypertrophy or strains may be inappropriate fibrosis measures in ESRD. Extracellular matrix turnover markers, e.g. TIMPs, may represent more specific biomarkers of fibrosis and molecular targets for therapeutics development.

This abstract and the presentation materials are available to members only; a login is required.

Join Here